— Circulating tumor DNA assay outperformed PET alone in predicting long-term outcomes
by Gregory Laub, Senior Director, Video, MedPage Today
July 16, 2026
• 1 min read
A study presented at the American Society of Clinical Oncology (ASCO) annual meeting suggested that circulating tumor (ct)DNA-based measurable residual disease (MRD) assessment may provide prognostic information for patients with relapsed or refractory follicular lymphoma treated with lisocabtagene maraleucel (liso-cel; Breyanzi).
